| 1206O Clinical subtyping of cancer from blood based on comprehensive epigenomic profiling S Baca, JH Seo, JE Berchuck, T El Zarif, RM Saliby, K Semaan, ... Annals of Oncology 34, S711, 2023 | | 2023 |
| 2360O The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as≥ second-line therapy for metastatic urothelial … BA McGregor, GP Sonpavde, L Kwak, X Gao, C Mantia, XX Wei, ... Annals of Oncology 34, S1199-S1200, 2023 | 2 | 2023 |
| A community partnership to house and care for complex patients S Gondi, SI Berchuck, RT Brown, M Hinderlie, L Easton, L Smith, ... NEJM catalyst innovations in care delivery 2 (8), 2021 | 3 | 2021 |
| A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer D Boiarsky, DC Gulhan, H Savignano, G Lakshminarayanan, HM McClure, ... Clinical Genitourinary Cancer 22 (2), 558-568. e3, 2024 | | 2024 |
| A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia DJ DeAngelo, D Neuberg, PC Amrein, JE Berchuck, M Wadleigh, ... Leukemia research 38 (4), 430-434, 2014 | 35 | 2014 |
| Abstract A029: Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation of renal cell carcinoma (RCC) K Semaan, TE Zarif, M Eid, V Shah, B Fortunato, RM Saliby, AH Nassar, ... Cancer Research 83 (16_Supplement), A029-A029, 2023 | | 2023 |
| Addition of germline testing to tumor-only sequencing improves detection of pathogenic germline variants in men with advanced prostate cancer JE Berchuck, D Boiarsky, R Silver, R Sunkara, HM McClure, HK Tsai, ... JCO Precision Oncology 6, e2200329, 2022 | 7 | 2022 |
| All-trans-Retinal Sensitizes Human RPE Cells to Alternative Complement Pathway–Induced Cell Death JE Berchuck, P Yang, BA Toimil, Z Ma, P Baciu, GJ Jaffe Investigative ophthalmology & visual science 54 (4), 2669-2677, 2013 | 17 | 2013 |
| An often-overlooked etiology of pleuritic chest pain JE Berchuck, S Patel Journal of General Internal Medicine 31, 138-138, 2016 | 4 | 2016 |
| Association of mental health treatment with outcomes for US veterans diagnosed with non–small cell lung cancer JE Berchuck, CS Meyer, N Zhang, CM Berchuck, NN Trivedi, B Cohen, ... JAMA oncology 6 (7), 1055-1062, 2020 | 37 | 2020 |
| Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping SC Baca, JH Seo, MP Davidsohn, B Fortunato, K Semaan, S Sotudian, ... nature medicine 30 (3), 907-907, 2024 | | 2024 |
| Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases J Mitchell, N Camacho, P Shea, KH Stopsack, V Joseph, O Burren, ... medRxiv, 2024 | | 2024 |
| Clinical considerations for the management of androgen indifferent prostate cancer JE Berchuck, PV Viscuse, H Beltran, A Aparicio Prostate cancer and prostatic diseases 24 (3), 623-637, 2021 | 39 | 2021 |
| Co-occurring BRCA2/SPOP mutations predict exceptional poly (ADP-ribose) polymerase inhibitor sensitivity in metastatic castration-resistant prostate cancer JJ Orme, F Taza, N De Sarkar, AK Tewari, SA Naqvi, IB Riaz, DS Childs, ... European Urology Oncology, 2023 | 1 | 2023 |
| Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer P Ravi, D Freeman, J Thomas, A Ravi, C Mantia, BA McGregor, ... Journal for Immunotherapy of Cancer 12 (2), 2024 | | 2024 |
| Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in patients with muscle-invasive bladder cancer (MIBC) undergoing trimodality therapy (TMT). IB Epstein, SA Berg, C Mantia, M Mossanen, A Saraf, MA Preston, A Ravi, ... Journal of Clinical Oncology 42 (16_suppl), e16606-e16606, 2024 | | 2024 |
| Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis JE Berchuck, SC Baca, HM McClure, K Korthauer, HK Tsai, PV Nuzzo, ... Clinical Cancer Research 28 (5), 928-938, 2022 | 35 | 2022 |
| Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling T El Zarif, CB Meador, X Qiu, JH Seo, MP Davidsohn, H Savignano, ... Clinical Cancer Research, 2024 | | 2024 |
| Detection of neuroendocrine prostate cancer through plasma-based epigenomic profiling. M Eid, K Semaan, JH Seo, MP Davidsohn, B Fortunato, ... Journal of Clinical Oncology 42 (4_suppl), 201-201, 2024 | | 2024 |
| Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes PV Nuzzo, JE Berchuck, K Korthauer, S Spisak, AH Nassar, S Abou Alaiwi, ... Nature medicine 26 (7), 1041-1043, 2020 | 221 | 2020 |
